The program will be held at the New Jersey Economic Development Authority’s (EDA) Commercialization Center for Innovative Technologies (CCIT) at 675 U.S. Hwy One, North Brunswick Township.
CCIT, one of the more significant incubation facilities in the nation dedicated to life sciences and biotechnology companies, is located at the Technology Centre of New Jersey, a 75-acre life sciences research park in the heart of New Jersey’s Research Corridor.
The program will also include a presentation by Oncoceutics, Inc. which is successfully leveraging SBIR funding to build its business, followed by a networking lunch and 1-to-1 conversations with NCI and NIAID representatives in the afternoon.
Scheduled speakers include:
- Todd Haim, Ph.D., Program Director, NCI SBIR Development Center
- Natalia Kruchinin, Ph.D., SBIR/STTR Program Coordinator, NIAID
- Michael Minnicozzi, Ph.D., Program Officer, NIAID
- Randy Harmon, NJSBDC Technology Commercialization Consultant
- Lee Schalop, M.D., Chief Operating Officer, Oncoceutics, Inc.
- Anthony Faugno, Certified Public Accountant, Partner, EisnerAmper
- Vincent Smeraglia, Executive Director, Rutgers Office of Research Commercialization
CCIT Manager Lenzie Harcum noted that eleven federal agencies, including the NIH and NSF, are obligated to commit approximately three percent of their annual extramural R&D budget to support entrepreneurs and small businesses undertaking research.
This commitment translates to approximately $2.5 billion annually in competitive grants to fund small businesses.
After registering, a representative of each company wishing to meet 1-on-1 with program participants should email email@example.com by September 11 and include a one-page overview of its technology, highlighting the specific objectives any approved SBIR and/or STTR funding would support.
Visit www.njsbdc.com/sbir to view the agenda or to sign up.